Evoke Pharma (NASDAQ: EVOK) reported Q1 EPS of ($0.45), $0.04 worse than the analyst estimate of ($0.41).

As of March 31, 2016, the Company’s cash and cash equivalents were approximately $6.1 million.

For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.